Dynamic clonal equilibrium and predetermined cancer risk in Barrett's oesophagus

Nature Communications

Volumn 7, Issue , 2016, Pages

  Martinez, Pierre ^a   Timmer, Margriet R ^b   Lau, Chiu T ^b   Calpe, Silvia ^b   Sancho Serra, Maria Del Carmen ^b   Straub, Danielle ^b   Baker, Ann Marie ^a   Meijer, Sybren L ^b   Kate, Fiebo J W Ten ^b   Mallant Hent, Rosalie C ^c,d   Naber, Anton H J ^d,e   Van Oijen, Arnoud H A M ^d,f   Baak, Lubbertus C ^d,g   Scholten, Pieter ^d,g   Böhmer, Clarisse J M ^d,h   Fockens, Paul ^a   Bergman, Jacques J G H M ^b,d   Maley, Carlo C ⁱ   Graham, Trevor A ^a   Krishnadath, Kausilia K ^b,d  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c Flevoziekenhuis ^*  (Netherlands)

^d Amsterdam Gastroenterological Association   (Netherlands)

^e TERGOOI HOSPITAL   (Netherlands)

^f Location Alkmaar   (Netherlands)

^g ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^h Infection and Immunology   (Netherlands)

ⁱ ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16; PROTON PUMP INHIBITOR;

CANCER; CELLS AND CELL COMPONENTS; CLONE; DIGESTIVE SYSTEM; EQUILIBRIUM; FLUORESCENCE; HEALTH RISK; HYBRIDIZATION;

ADULT; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CLONAL EVOLUTION; COHORT ANALYSIS; CYTOLOGY; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROSPECTIVE STUDY; TIME; ADENOCARCINOMA; AGED; BIOPSY; CARCINOGENESIS; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; EPIDEMIOLOGICAL MONITORING; ESOPHAGOSCOPY; ESOPHAGUS; ESOPHAGUS TUMOR; FOLLOW UP; GENETICS; INCIDENCE; MULTICENTER STUDY; MUTATION; NETHERLANDS; PATHOLOGY; PROCEDURES; SINGLE CELL ANALYSIS; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; BIOPSY; CARCINOGENESIS; CLONAL EVOLUTION; DISEASE PROGRESSION; EPIDEMIOLOGICAL MONITORING; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; ESOPHAGUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INCIDENCE; MALE; MIDDLE AGED; MUTATION; NETHERLANDS; PROSPECTIVE STUDIES; SINGLE-CELL ANALYSIS;

EID: 84983233354     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12158     Document Type: Article

References (32)

1. Nowell, P. C. The clonal evolution of tumor cell populations. Science 194, 23-28 (1976).
2. Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481, 306-313 (2012).
3. Reid, B. J., Li, X., Galipeau, P. C. & Vaughan, T. L. Barrett's oesophagus and oesophageal adenocarcinoma: Time for a new synthesis. Nat. Rev. Cancer 10, 87-101 (2010).
4. Weaver, J. M. J. et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat. Genet. 46, 837-843 (2014).
5. Dulak, A. M. et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat. Genet. 45, 478-486 (2013).
6. Agrawal, N. et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov. 2, 899-905 (2012).
7. Spechler, S. J. & Souza, R. F. Barrett's esophagus. N. Engl. J. Med. 371, 836-845 (2014).
8. Sikkema, M., de Jonge, P. J. F., Steyerberg, E. W. & Kuipers, E. J. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: A systematic review and meta-Analysis. Clin. Gastroenterol. Hepatol. 8, 235-244 (2010).
9. Hvid-Jensen, F., Pedersen, L., Drewes, A. M., Sørensen, H. T. & Funch-Jensen, P. Incidence of adenocarcinoma among patients with Barrett's esophagus. N. Engl. J. Med. 365, 1375-1383 (2011).
10. Phoa, K. et al. Radiofrequency ablation versus endoscopic surveillance for patients with barrett esophagus and low-grade dysplasia: A randomized clinical trial. JAMA 311, 1209-1217 (2014).
11. American Gastroenterological Association et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 140, 1084-1091 (2011).
12. Orman, E. S., Li, N. & Shaheen, N. J. Efficacy and durability of radiofrequency ablation for Barrett's esophagus: systematic review and meta-Analysis. Clin. Gastroenterol. Hepatol. 11, 1245-1255 (2013).
13. Maley, C. C. et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet. 38, 468-473 (2006).
14. Kostadinov, R. L. et al. NSAIDs modulate clonal evolution in Barrett's esophagus. PLoS Genet. 9, e1003553 (2013).
15. Merlo, L. M. F. et al. A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev. Res. (Phila.) 3, 1388-1397 (2010).
16. Davelaar, A. L. et al. Aberrant TP53 detected by combining immunohistochemistry and DNA-FISH improves Barrett's esophagus progression prediction: A prospective follow-up study. Genes Chromosomes Cancer 54, 82-90 (2014.
17. Leedham, S. J. et al. Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus. Gut 57, 1041-1048 (2008).
18. Maley, C. C. et al. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res. 64, 7629-7633 (2004).
19. Barrett, M. T. et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat. Genet. 22, 106-109 (1999).
20. Kastelein, F. et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut 62, 1676-1683 (2013).
21. Bird-Lieberman, E. L. et al. Population-based study reveals new riskstratification biomarker panel for Barrett's esophagus. Gastroenterology 143, 927-935.e3 (2012).
22. Galipeau, P. C. et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 4, e67 (2007).
23. Fitzgerald, R. C. et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 63, 7-42 (2014).
24. Spechler, S. J. Barrett esophagus and risk of esophageal cancer: A clinical review. JAMA 310, 627-636 (2013).
25. Desai, T. K. et al. The incidence of oesophageal adenocarcinoma in nondysplastic Barrett's oesophagus: A meta-Analysis. Gut 61, 970-976 (2012).
26. Rudolph, R. E. et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann. Intern. Med. 132, 612-620 (2000).
27. Menke-Pluymers, M. B., Hop, W. C., Dees, J., van Blankenstein, M. & Tilanus, H. W. Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus. The Rotterdam Esophageal Tumor Study Group. Cancer 72, 1155-1158 (1993).
28. Li, X. et al. Temporal and spatial evolution of somatic chromosomal alterations: A case-cohort study of Barrett's esophagus. Cancer Prev. Res. (Phila.) 7, 114-127 (2014).
29. Kastelein, F. et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. Clin. Gastroenterol. Hepatol. 11, 382-388 (2013).
30. Maley, C. C. Multistage carcinogenesis in Barrett's esophagus. Cancer Lett. 245, 22-32 (2007).
31. Schlemper, R. J. et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 47, 251-255 (2000).
32. Rygiel, A. M. et al. Efficient automated assessment of genetic abnormalities detected by fluorescence in situ hybridization on brush cytology in a Barrett esophagus surveillance population. Cancer 109, 1980-1988 (2007).